Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical stage immuno-oncology company, renowned for its innovation in next-generation cancer immunotherapies. Headquartered in Gaithersburg, MD, Sensei leverages its proprietary TMAb™ (Tumor Microenvironment Activated biologics) platform to develop cutting-edge therapeutics designed to harness the body's immune system against cancer. The company’s leading product candidates include SNS-101, SNS-102, SNS-103, and SNS-201, all of which are conditionally active antibodies targeting different immunosuppressive markers within the tumor microenvironment.
Sensei’s flagship candidate, SNS-101, is designed to block the VISTA (V-domain Ig suppressor of T cell activation) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. SNS-101 is currently undergoing a multi-center Phase 1/2 clinical trial, evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy as both a monotherapy and in combination with Regeneron's PD-1 inhibitor, Libtayo® (cemiplimab), in patients with advanced solid tumors. Initial data are promising, showing SNS-101 to be well-tolerated and demonstrating clinical activity, particularly in tumor types typically resistant to PD-1 monotherapy.
Other promising candidates include SNS-102, targeting VSIG-4 (V-Set and Immunoglobulin Domain Containing 4), and SNS-103, targeting CD39 (ecto-nucleoside triphosphate diphosphohydrolase-1), as well as SNS-201, a conditionally active VISTAxCD28 bispecific antibody. The company has established key academic collaborations, including with Brown University, to bolster its research and development efforts.
Financially, Sensei maintains a strong balance sheet with cash reserves projected to fund operations into the second half of 2025. Recent financial updates show reduced R&D and G&A expenses due to strategic restructuring, leading to a narrower net loss. The company is focused on advancing its clinical trials, with expected milestones including initial combination safety and pharmacokinetic data for SNS-101 in early 2024, followed by topline monotherapy data later in the year.
For more information, visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.
Sensei Biotherapeutics (Nasdaq: SNSE) reported third-quarter results for 2022, showing a net loss of $13.4 million, up from $9.7 million a year earlier. The company's cash position was $116.6 million, expected to fund operations into Q1 2025. Sensei highlighted favorable preclinical data for SNS-101, which demonstrated a superior cytokine release profile and advanced anti-tumor effects. Upcoming events include a virtual KOL webinar on November 21 and presentations at the SITC Annual Meeting.
Sensei Biotherapeutics (NASDAQ: SNSE) announced a KOL webinar titled “Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint,” scheduled for November 21, 2022, at 2:15 p.m. ET. Featuring Dr. Robert Schreiber, the webinar will cover VISTA's role in immuno-oncology and present data on SNS-101, a VISTA-blocking antibody designed for the low pH tumor microenvironment. Participants can register online, and a recording will be available afterward. The event will conclude with a Fireside Chat with Dr. Schreiber and a live Q&A session.
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) will present at the 13th Annual Jefferies Global Healthcare Conference in London on November 17, 2022, at 7:25 a.m. GMT. The presentation, led by CEO John Celebi, will highlight the company's focus on developing innovative immuno-oncology therapeutics, particularly through its TMAb™ platform. The lead candidate, SNS-101, targets the VISTA checkpoint in the tumor microenvironment to enhance T cell activation against tumors. A webcast of the presentation will be available on Sensei’s website for approximately 90 days.
Sensei Biotherapeutics (Nasdaq: SNSE) has announced its participation in the SITC 37th Annual Meeting in Boston from November 8-12, 2022. The company will present two posters highlighting their advancements in immuno-oncology. The first presentation will focus on novel T-cell receptors related to the VSIG4 macrophage receptor, while the second will discuss SNS-101, an antibody that enhances anti-PD-1 sensitivity in tumors. These advancements underscore Sensei's commitment to developing innovative cancer therapeutics using their TMAb and ImmunoPhage platforms.
Sensei Biotherapeutics (NASDAQ: SNSE) presented promising data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference. Preclinical results indicate SNS-101 enhances anti-tumor effects when combined with anti-PD-1 antibodies, achieving five complete responses in a resistant tumor model. The antibody also exhibits a favorable pharmacokinetic profile, reducing the risk of cytokine release syndrome compared to traditional VISTA antibodies. This data may support SNS-101's potential for broad oncological applications.
Sensei Biotherapeutics (Nasdaq: SNSE) announced it will present new preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference in New York from September 28 to October 1, 2022. The poster presentation is scheduled for September 30, highlighting SNS-101's favorable pharmacokinetic properties and its potential to enhance anti-PD-1 responses. This aligns with Sensei's mission of developing next-generation cancer therapeutics.
Sensei Biotherapeutics (NASDAQ: SNSE) announced preliminary preclinical data for SNS-101, an antibody targeting the VISTA immune checkpoint. Results indicate that SNS-101 effectively overcomes pharmacokinetic challenges and enhances anti-tumor effects when combined with anti-PD-1 antibodies. Additionally, SNS-101 shows a favorable pharmacokinetic profile, with a median half-life of approximately three weeks. Ongoing IND-enabling studies aim to evaluate SNS-101's potential for treatment in solid cancers, with an IND filing planned for the first half of 2023.
Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in two key investor conferences in September 2022, aimed at exploring the latest in immuno-oncology developments.
The conferences are:
- Citi’s 17th Annual Biopharma Conference (September 7-8, Boston, MA)
- Wells Fargo’s 2022 Healthcare Conference (September 7-9, Boston, MA)
Interested portfolio managers and analysts can arrange meetings with company management through their respective representatives.
Sensei Biotherapeutics (NASDAQ: SNSE) announced progress in its clinical programs, including pre-IND feedback from the FDA for SNS-101, an anti-VISTA antibody, expected to file an IND in the first half of 2023. The company will present new pharmacokinetic data in non-human primates in Q3 2022. The strong financial position, with cash equivalents of $123.7 million, supports operations through Q1 2025. Research and development expenses increased to $6.4 million due to higher headcount and inflation. The net loss was reported at $10.5 million for Q2 2022.
On June 1, 2022, Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Patrick Gallagher as Chief Business Officer. Gallagher, an experienced biotech executive, will leverage his nearly 20 years in the pharmaceutical and biotech sectors to enhance Sensei's strategic initiatives. His past roles include significant contributions to various reputable companies and investment banking firms. This leadership change is expected to strengthen the company's position during critical phases of program advancements.
FAQ
What is the current stock price of Sensei Biotherapeutics (SNSE)?
What is the market cap of Sensei Biotherapeutics (SNSE)?
What is Sensei Biotherapeutics, Inc.?
What products is Sensei developing?
What is SNS-101?
What are the recent achievements of the company?
Where is Sensei Biotherapeutics headquartered?
What is the TMAb™ platform?
What financial status does Sensei Biotherapeutics have?
Who are Sensei's key collaborators?
What are the anticipated milestones for SNS-101?
Where can I find more information about Sensei Biotherapeutics?
